Targeting the Cancer Cell Switch That Won't Turn Off — A Full Breakdown of the BeOne–Revolution RAS Four-Drug Alliance

• Doubling Pancreatic Cancer Survival: The Truth About the RAS Drugs BeOne Just Bet Big On
• The 40-Year "Undruggable" Target RAS Is Finally Cracked — Everything About Tri-Complex Technology
• Why Were Only Korea and Japan Left Out? Three Hidden Motives in the BeOne–Revolution RAS Deal
• What Is a RAS(ON) Inhibitor? Why Daraxonrasib, Zoldonrasib and Two Others Are Reshaping Oncology   

🧬 Targeting the Cancer Cell's "Switch That Won't Turn Off" — What Makes the BeOne–Revolution RAS Alliance of Four Drugs a Game Changer

Introduction: Why This Single Deal Shook the Oncology World

In August 2026, the global pharmaceutical company BeOne Medicines joined hands with the U.S.-based Revolution Medicines. On the surface, it reads like a routine partnership announcement — "co-develop four cancer drugs and hand over regional rights in parts of Asia." But look inside the contract and the story changes. This is a fairly bold gamble aimed squarely at RAS, the wall that has been called an "undruggable target" for the past 40 years and has frustrated one leading drugmaker after another.

In this article, we'll step beyond the reported facts. We'll walk through what RAS actually is and why the whole industry is chasing it, how Revolution's four drugs differ from existing treatments, and why BeOne jumped into this arena putting up its own capital. Difficult terms will be unpacked naturally along the way, so even readers new to the field can follow to the end without trouble.

📌 Starting With the Framework of the Deal

This collaboration is built on two tracks.

One track is joint clinical development. The two companies will study combination therapy — pairing Revolution's four clinical-stage drugs with BeOne's own investigational cancer candidates — in patients with so-called "RAS-addicted cancers," where mutations in the RAS gene act as the engine of tumor growth. The phrase "RAS-addicted" may sound unfamiliar; it's an academic term for a state in which certain cancer cells survive and multiply relying solely on RAS signaling, almost as if dependent on it. Put the other way around, it means such cancers may well collapse if that RAS signal is cut off.

The other track is a regional commercialization agreement. BeOne secures exclusive development and sales rights to these four drugs in select Asian markets excluding Korea and Japan. In return, Revolution receives milestone payments (amounts paid each time a defined goal is reached under a technology-export deal) as development and sales progress stage by stage, plus royalties (running fees) taking a set percentage once actual sales occur. One notable point is that Korea and Japan were excluded from the deal territory — something we'll revisit later.

There's one more piece. BeOne agreed to fund and personally lead a global registrational Phase 3 trial for one of Revolution's four drugs. Rather than a passive partner that merely licenses in the rights, it has chosen a position closer to a "co-equity participant" that shoulders the risks and costs of development alongside its partner. For reference, a registrational trial is a clinical study designed with the goal of obtaining marketing approval from regulators.

🔬 Getting the Concept First: What Exactly Is RAS?

Without understanding RAS, the protagonist of this story, you can grasp only half the weight of this deal.

The cells in our bodies constantly exchange signals about "when to grow and when to stop." RAS is a kind of molecular switch protein sitting at the crossroads where those signals travel. Under normal conditions, when a surface receptor receives a growth signal, RAS briefly turns on (ON) and then turns itself off (OFF) once the job is done. By repeating this on-and-off cycle, it finely tunes the pace of cell growth.

The trouble is that when a mutation arises in the RAS gene, this switch gets stuck in the ON position and won't shut off. Growth signals pour out around the clock, and the cell proliferates out of control. This is cancer.

So how big a role does RAS play? It's found in more than 90% of pancreatic cancer (pancreatic ductal adenocarcinoma) patients, roughly 40–50% of colorectal cancers, and a substantial share of lung cancer (non-small cell lung cancer). Some estimates put one in five of all cancer patients as being related to it. That's why RAS has long been a "summit that must be conquered" for cancer-drug developers.

Yet why couldn't it be conquered for 40 years? Because the surface of the RAS protein is so smooth that it has almost no deep "pocket" for a drug to latch onto and settle in. It was like a door with no keyhole at all. Hence the enduring nickname, "undruggable target."

⚙️ The Difference That Decided the Match: Hitting 'RAS(ON),' Not 'RAS(OFF)'

This is precisely where the heart of the deal lies.

The first-generation KRAS-targeted drugs that emerged after 2021 (sotorasib and adagrasib are representative) worked by binding to RAS in its off state — RAS(OFF). It's a strategy of locking the switch during the brief moment it flips off. Groundbreaking as it was, its limits were clear. It worked against only one specific mutation, KRAS G12C, and cancer cells quickly acquired resistance, so the effect didn't last.

Revolution's four drugs start from the opposite idea. They attack RAS directly in its activated, on state — RAS(ON). Since the true driver of cancer is this "switched-on RAS," the aim is to strike the root of the problem head-on.

The problem, as noted, was that RAS's surface offers no place for a drug to bind. Revolution overcame this wall with an original approach called the tri-complex.

A tri-complex is, literally, "a cluster in which three substances fuse into one." The three here are, first, the drug Revolution created; second, a protein called cyclophilin A that drifts abundantly throughout the cell; and third, the target RAS protein. Because these three lock together in sequence to complete a single structure, it's called a "tri(triple)-complex."

Let's picture the sequence. When the drug enters the body, it doesn't rush straight at RAS; instead, it first grabs cyclophilin A, which is everywhere inside the cell. Cyclophilin A is originally an abundant, common "helper protein" that assists other proteins in folding into their proper shapes within the cell. Using this common helper as its partner, the drug forms a two-as-one complex: "drug + cyclophilin A." Up to this stage, it's a binary complex.

The real trick comes next. This bulked-up "drug + cyclophilin A" complex finally goes and binds to the RAS protein. At that instant, the tri-complex — three substances (drug, cyclophilin A, and RAS) fused into one — is complete.

The true brilliance of the technology lies in why such a roundabout route was chosen. As explained, RAS's surface is smooth, with no "pocket" for a drug to grip on its own. It was a door without a keyhole. Revolution's idea was: don't try to open the door with the drug alone — insert a bulky partner, cyclophilin A, to forcibly create a contact surface. By analogy, when there's no good spot to drive a nail into a wall, you first place a bracket (cyclophilin A) and fix the nail (the drug) onto it. The new contact surface, forged by the drug and cyclophilin A becoming one, artificially creates a "binding site" on RAS that never existed before.

This approach has two decisive strengths. One is that it targets the switched-on RAS(ON) state directly. Unlike first-generation drugs that had to wait for the brief moment RAS turned off (the OFF state), the tri-complex seizes the active RAS that actually drives cancer and shuts down its function head-on. The other is that, because cyclophilin A is so plentiful inside the cell, the drug rarely spins uselessly for lack of a partner, allowing it to attack the target efficiently.

In short, the essence of tri-complex technology is a strategy in which the drug itself creates the binding site against a "target with no place to bind." This conceptual shift was the very key that first cracked open the RAS wall — immovable for 40 years — and all four drugs, starting with daraxonrasib, stand on this principle. Once you grasp this point, it becomes clear that Revolution's approach is not merely "one more KRAS drug" but the invention of an entirely new methodology for gripping the target.

💊 The Four Drugs: What Each One Aims At

The four drugs in the combination trials each target a different spot. This "division of roles" is the very strength of the portfolio.

Daraxonrasib (development code RMC-6236) is the flagship among them. Rather than seizing just one specific mutation, it's a multi-selective drug that broadly inhibits many kinds of mutant RAS as well as normal RAS. Covering multiple mutations at once gives it a wide range of use. In fact, in a Phase 3 trial (RASolute 302) of about 500 previously treated metastatic pancreatic cancer patients, it delivered results that cut the risk of death by 60% versus standard chemotherapy and nearly doubled median overall survival from 6.7 to 13.2 months. Given that pancreatic cancer is a notoriously intractable cancer with an extremely low 5-year survival rate, these figures sent considerable ripples through the industry, and the U.S. FDA accepted the drug's new drug application and began its review in July 2026. For reference, median overall survival means the survival time of the patient sitting exactly in the middle when patients are lined up in order of survival duration; it's regarded as a more reliable metric than the average because it's less swayed by extreme values.

Zoldonrasib (RMC-9805) precisely targets the KRAS G12D mutation. G12D is the most common mutation in pancreatic and colorectal cancer, yet an area with no proper targeted therapy — so unmet demand is large. In early trials, about half (roughly 52%) of previously treated KRAS G12D–mutant non-small cell lung cancer patients showed a response with visibly shrinking tumors, raising expectations.

Elironrasib (RMC-6291) targets the KRAS G12C mutation — the very mutation those first-generation drugs mentioned earlier went after — but elironrasib differs in that it takes the RAS(ON) approach.

RMC-5127 is an oral (taken by mouth) drug that selectively inhibits the KRAS G12V mutation. G12V is the second most common mutation driving RAS-addicted cancers and, likewise, a target that has long been hard to attack. It's at the earliest development stage of the four.

In sum, daraxonrasib handles "broad coverage," while zoldonrasib, elironrasib, and RMC-5127 each precisely strike the key mutations G12D, G12C, and G12V. As a portfolio that doesn't stake its fate on a single molecule but spreads risk across several fronts, it's a strategically shrewd design.

🤝 What BeOne Adds: The Logic of Combination

BeOne aims for synergy by pairing in two of its own candidates.

BGB-58067 is a PRMT5 inhibitor. PRMT5 is an enzyme involved in cell survival, and there's an intriguing trap principle hidden here. In some cancer cells, a gene called MTAP is deleted entirely (about 10–15% of all cancers, higher in certain types). When this deletion occurs, a substance called MTA accumulates inside the cell, and the cancer cell becomes uniquely dependent on PRMT5. Inhibiting PRMT5 in this state produces an effect that selectively kills only the cancer cells while normal cells remain unharmed. This phenomenon — where cells die only when two defects overlap — is called synthetic lethality. BGB-58067 is notable for being designed to work better in an MTA-accumulated environment (MTA-cooperative), lowering the toxicity problem of earlier PRMT5 inhibitors that also damaged normal blood cells.

BG-T187 is an antibody with a more complex structure. It's an EGFR×MET×MET trispecific antibody designed to simultaneously grab the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (MET), while binding to two different spots (epitopes) on MET. Both EGFR and MET fuel tumor growth and are notorious signaling pathways that cancer cells quietly open as bypass routes, especially when resistance to targeted therapy develops. Here, an "epitope" means a specific spot on an antigen where an antibody binds; when a single antibody grips two spots on MET at once, it can block the target more firmly and forcefully.

The core hypothesis of the combination is this. Even if a RAS(ON) inhibitor cuts the main growth signal, cancer cells try to survive by opening bypass routes such as EGFR/MET. So if you block RAS and simultaneously shut down those bypasses too, might you draw out deeper responses and delay the point at which resistance emerges? The initial combination trials will start with pairings of BGB-58067 and BG-T187 with either daraxonrasib or zoldonrasib.

💡 One Step Further: Questions We Easily Miss

Skim the news and it's easy to stop at the conclusion that "they'll co-develop good drugs together." But to read this deal properly, we need to examine a few more angles.

Why, of all things, were Korea and Japan left out? Excluding these two countries from what is billed as an Asian rights deal is no accident. Korea and Japan have sophisticated regulatory systems, high drug prices, and large oncology markets. From Revolution's standpoint, it's natural to read this as a result reflecting bargaining leverage — leaving room to enter directly later, or to partner separately on better terms. In short, this deal isn't "handing over all of Asia" but rather a careful split in which both sides keep their prime markets while cooperating only in the remaining territories.

The meaning of BeOne shouldering the Phase 3 cost directly is also worth noting. In a typical licensing-in deal, the in-licensing company need only mind its own region. Yet BeOne took on an entire global Phase 3. This is a move to secure a stake and a voice as a development partner, beyond a mere sales partner. Contributing directly to global data generation lets it use that data for approval in its own regions and increases its influence over the direction of development.

Why did BeOne buy in someone else's drugs even though it has its own pipeline? In fact, the company is already running its own RAS strategies — a CNS-penetrant RAS(ON) inhibitor, a KRAS degrader, a RAS-based antibody-drug conjugate (ADC), and more. Even so, bringing in Revolution's clinically validated portfolio can be read as a dual move: hedging the risk of "missing the market while waiting for our own to be finished," while immediately building its presence in the vast RAS market right now. Running in-house development and external in-licensing side by side is also a textbook strategy commonly used in oncology, where the risk of a single asset's failure is high.

What is the real risk of the RAS(ON) strategy? There's a point that optimism-heavy reporting tends to skip. RAS is a protein that performs indispensable functions in normal cells too. For a drug like daraxonrasib, which broadly inhibits not only mutant RAS but normal RAS as well, long-term success or failure hinges on how heavy a burden (toxicity) it places on normal tissue and how wide its "therapeutic window" is (the dose range where it's effective yet the toxicity is tolerable). Moreover, no matter how novel the mechanism, cancer cells eventually find new resistance routes. This is exactly why BeOne's combination strategy exists — and at the same time, it's the greatest risk should the combination trials fail to deliver the expected synergy. Ultimately, the success or failure of this deal rests not on the performance of any single drug but on whether the "chemistry of the combination" can be proven in actual patients.

🧭 Closing: How Should We Read This Deal?

This collaboration carries significance from three angles. First, the symbolism that RAS — long deemed "untouchable" — has now risen to a target with clinically proven, real extension of survival. Second, confirmation of a trend shifting from an era of betting on a single mutation and a single drug to an era of multi-mutation portfolios and combination strategies. Third, BeOne's ambition to position itself as a global oncology player beyond Asia by directly investing capital and capabilities in global development, rather than merely licensing in rights.

Of course, all of this remains for the forthcoming combination trial data to prove. However impressive daraxonrasib's pancreatic cancer results may be, the tough homework of combination synergy and overcoming resistance still lies ahead. Even so, this deal can be called a clear milestone showing that oncology's long-held dream of conquering RAS has at last crossed from the stage of "possibility" into the stage of "execution."